2024 YHLO Global Partner Conference
On July 18th, the 2024 YHLO Global Partner Conference was grandly held in Shenzhen. Over a hundred esteemed partners and guests from nearly 40 countries and regions around the world attended the event. Centered on the theme "Connecting the Future," the conference united the exceptional wisdom and steadfast strength of our global partners, collectively envisioning a promising landscape for future collaborative development.
Mr. Kunhui Hu, Chairman of YHLO, delivered the opening speech, welcoming and thanking all the guests and partners who traveled from afar. In his speech, he provided a brief analysis of the current development status of the IVD industry and reviewed YHLO’s rapid development in the innovative environment of Shenzhen, China. Mr. Hu firmly stated that in the wave of global IVD industry growth, YHLO will continuously increase investment in R&D innovation, product quality, and customer service. He emphasized YHLO's commitment to becoming a leading global company in the autoimmune diagnostics field within the next decade, further advancing human health diagnostics technology.
During the conference, Mr. Li Wei, Director of the International Business Unit at YHLO, presented the significant achievements of YHLO’s international business in recent years. He shared unforgettable moments of collaboration with international partners and outlined YHLO’s future international strategies and plans. Mr. Li emphasized that YHLO will always uphold the principle of customer-first, offering personalized, precise, and high-quality services to help clients expand their local markets and build distinctive competitive advantages.
Representatives from YHLO’s instrument and reagent R&D Centers, Manufacture Center, and Gendow Sequencing Biotechnology, also spoke at the event. They provided detailed insights into the current status and development plans of various modules, helping clients and partners gain a deeper understanding of YHLO’s potential and strength, thereby strengthening trust and support for YHLO products.
The conference also featured top domestic and international experts in autoimmune diseases, reproductive health, and cardiovascular health, who shared cutting-edge research trends and innovative results. This further boosted confidence in the industry’s development.
The conference agenda was rich and vibrant, with every segment being a highlight. Representatives from global partners actively participated, sharing valuable experiences in regional market. They expressed that this conference gave them a deeper understanding of YHLO and reinforced their commitment to closer collaboration with YHLO to explore international markets together.
The grand evening banquet was filled with laughter and joy, as YHLO executives and guests gathered to celebrate the successful conclusion of the 2024 Global Partner Conference.
This visit to China not only showcased YHLO’s strength and charm but also united the consensus and power of global partners. Taking this grand event as an opportunity, YHLO will continue to strengthen and expand its global partnerships. With the momentum of "Connecting the Future," YHLO aims to collaborate with more internaltional partners, ensuring the global success of its world-class products, and continuously contributing to the development of global human health.
Attachments:
Next
Previous Page
Next Page
MORE NEWS
n November 18, 2025, YHLO’s 2025 Global Core Distributors Conference was successfully held in Düsseldorf, Germany. Under the theme “Academia-Driven, Shared Value,” the meeting brought together representatives from more than 30 core distributors worldwide. YHLO’s founder, Mr. Deming Hu, and Chairman, Mr. Kunhui Hu, led the company’s executive team to attend and discuss strategic development with partners.
2025-11-20
YHLO Secures Approval for the World’s First sCD146 CLIA Assay
YHLO has obtained approval from the Guangdong Medical Products Administration for its soluble CD146 (sCD146) CLIA assay, marking a major milestone in central nervous system (CNS) disease diagnostics. YHLO is now the first company worldwide to offer an sCD146 test for cerebrospinal fluid, bringing its total CLIA assay portfolio in China to 173.
2025-11-18
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
